Berkay Şahin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Berkay Şahin has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Elif Nur Şen Demirtaş
Department of Child and Adolescent Psychiatry, Ankara Etlik City Hospital, Ankara
2 shared publications - Meryem Kaşak
Department of Child and Adolescent Psychiatry, Ankara Etlik City Hospital, Ankara, Türkiye
2 shared publications - Sidre Nur Karakolcu
Department of Child and Adolescent Psychiatry, Ankara Etlik City Hospital, University of Health Sciences. Ankara / Türkiye
2 shared publications - Yusuf Selman Çelik
Department of Child and Adolescent Psychiatry, Ankara Etlik City Hospital, Ankara, Turkey
2 shared publications - Ahmet Furkan Kaya
Department of Child and Adolescent Psychiatry University of Health Sciences Ankara Etlik City Hospital Ankara Türkiye
1 shared publication - Ayşegül Efe
Department of Child and Adolescent Psychiatry, Ankara Etlik City Hospital, University of Health Sciences, Ankara, Türkiye
1 shared publication
Latest Publications
- Open Access
- 12 March 2026
- Published by Kastamonu University in Kastamonu Medical Journal
- Vol. 6 (1) , 64-71
Clinical and adverse effect profiles of paediatric polypharmacy by gender and ADHD status
Aims: This study aims to investigate the prevalence of concurrent psychotropic polypharmacy systematically, its associated adverse effects, and their relationship with individual factors such as diagnosis and gender in a child and adolescent outpatient population. While most existing literature on polypharmacy focuses on adults, there is a lack of recent, field-based data concerning children and adolescents.Methods: Among 4,928 outpatient admissions in January 2024, 595 children receiving two or more concurrent psychotropic medications were included. Polypharmacy was operationalized as the concurrent use of two or more psychotropic medication classes for a minimum duration of 30 consecutive days, consistent with thresholds described in previous guidelines (e.g., AACAP, NICE). Over a six-month follow-up, diagnostic profiles, medication regimens, comorbidities, adverse effects, and adherence were evaluated using clinical records and national e-Nabız data.Results: The sample was 57.1% male, with a median age of 13. Polypharmacy was most common among 16–18-year-olds. ADHD (52.8%), generalized anxiety disorder (19.5%), and depression/dysthymia (9.2%) were the most frequent diagnoses. Comorbidity was present in 76.6% of cases. Anxiety and mood disorders were more common in females, whereas specific learning disorder and enuresis were more prevalent in males. Stimulant-antipsychotic combinations were more typical in males; antidepressant-antipsychotic combinations were more common in females. Reported adverse effects included sleep disturbances, appetite changes, and irritability, with no significant differences between medication groups.Conclusion: Polypharmacy was more frequent in adolescents and those with ADHD, anxiety, or depression. Gender differences in medication patterns likely reflect underlying psychopathology. Given the high rates of adverse effects, structured monitoring protocols, including sleep and appetite checklists, should be routinely implemented. The findings support the integration of scheduled medication reviews and age- and gender-sensitive pharmacotherapy planning in child and adolescent psychiatry.
- 12 March 2026
- Published by Kastamonu University in Kastamonu Medical Journal
- Vol. 6 (1) , 64-71
Open AccessClinical and adverse effect profiles of paediatric polypharmacy by gender and ADHD status
Aims: This study aims to investigate the prevalence of concurrent psychotropic polypharmacy systematically, its associated adverse effects, and their relationship with individual factors such as diagnosis and gender in a child and adolescent outpatient population. While most existing literature on polypharmacy focuses on adults, there is a lack of recent, field-based data concerning children and adolescents.Methods: Among 4,928 outpatient admissions in January 2024, 595 children receiving two or more concurrent psychotropic medications were included. Polypharmacy was operationalized as the concurrent use of two or more psychotropic medication classes for a minimum duration of 30 consecutive days, consistent with thresholds described in previous guidelines (e.g., AACAP, NICE). Over a six-month follow-up, diagnostic profiles, medication regimens, comorbidities, adverse effects, and adherence were evaluated using clinical records and national e-Nabız data.Results: The sample was 57.1% male, with a median age of 13. Polypharmacy was most common among 16–18-year-olds. ADHD (52.8%), generalized anxiety disorder (19.5%), and depression/dysthymia (9.2%) were the most frequent diagnoses. Comorbidity was present in 76.6% of cases. Anxiety and mood disorders were more common in females, whereas specific learning disorder and enuresis were more prevalent in males. Stimulant-antipsychotic combinations were more typical in males; antidepressant-antipsychotic combinations were more common in females. Reported adverse effects included sleep disturbances, appetite changes, and irritability, with no significant differences between medication groups.Conclusion: Polypharmacy was more frequent in adolescents and those with ADHD, anxiety, or depression. Gender differences in medication patterns likely reflect underlying psychopathology. Given the high rates of adverse effects, structured monitoring protocols, including sleep and appetite checklists, should be routinely implemented. The findings support the integration of scheduled medication reviews and age- and gender-sensitive pharmacotherapy planning in child and adolescent psychiatry.
- Open Access
- 26 February 2025
- Published by Wiley in Psycho-Oncology
- Vol. 34 (3) , e70112
Psycho‐Oncological Issues in a Pediatric Sample: Two Years Follow‐Up Data of Consultation Liaison Psychiatry
Background: Pediatric oncology patients encounter substantial psychosocial and psychiatric challenges alongside physical illness and treatment burdens. Consultation‐Liaison Psychiatry (CLP) is critical for addressing these young patients' mental health needs within a broader healthcare framework. Socioeconomic disparities, family dynamics, and educational interruptions further complicate the psychiatric landscape in pediatric oncology.Aims: This study aims to explore the sociodemographic and psychiatric profiles of pediatric oncology patients referred to CLP services.Methods: A retrospective cross‐sectional study was conducted on 97 pediatric oncology patients who received CLP consultations over two years. Data included sociodemographic details, clinical history, and psychiatric diagnoses based on structured clinical interviews. Statistical analyses, including multivariate logistic regression, examined relationships between psychiatric outcomes and variables such as SES, educational status, and clinical factors.Results: The sample was predominantly of low SES (72.2%), with depression, adjustment disorders, and sleep disorders frequently observed. Patients unable to continue formal education due to their oncological disease and treatment process showed higher rates of depression. Significant associations emerged between psychopathology and factors such as lower SES, older parental age, and steroid use, although the predictive strength was modest. Most psychiatric consultations occurred due to observed psychiatric complaints rather than proactive psychosocial support, highlighting a reactive rather than preventive approach in CLP practice.Conclusions: Findings highlight the importance of early, structured psychiatric intervention and a proactive CLP approach to mitigate the psychiatric impact on pediatric oncology patients. Addressing SES‐based disparities and supporting educational continuity are essential for holistic pediatric cancer care.
- 26 February 2025
- Published by Wiley in Psycho-Oncology
- Vol. 34 (3) , e70112
Open AccessPsycho‐Oncological Issues in a Pediatric Sample: Two Years Follow‐Up Data of Consultation Liaison Psychiatry
Background: Pediatric oncology patients encounter substantial psychosocial and psychiatric challenges alongside physical illness and treatment burdens. Consultation‐Liaison Psychiatry (CLP) is critical for addressing these young patients' mental health needs within a broader healthcare framework. Socioeconomic disparities, family dynamics, and educational interruptions further complicate the psychiatric landscape in pediatric oncology.Aims: This study aims to explore the sociodemographic and psychiatric profiles of pediatric oncology patients referred to CLP services.Methods: A retrospective cross‐sectional study was conducted on 97 pediatric oncology patients who received CLP consultations over two years. Data included sociodemographic details, clinical history, and psychiatric diagnoses based on structured clinical interviews. Statistical analyses, including multivariate logistic regression, examined relationships between psychiatric outcomes and variables such as SES, educational status, and clinical factors.Results: The sample was predominantly of low SES (72.2%), with depression, adjustment disorders, and sleep disorders frequently observed. Patients unable to continue formal education due to their oncological disease and treatment process showed higher rates of depression. Significant associations emerged between psychopathology and factors such as lower SES, older parental age, and steroid use, although the predictive strength was modest. Most psychiatric consultations occurred due to observed psychiatric complaints rather than proactive psychosocial support, highlighting a reactive rather than preventive approach in CLP practice.Conclusions: Findings highlight the importance of early, structured psychiatric intervention and a proactive CLP approach to mitigate the psychiatric impact on pediatric oncology patients. Addressing SES‐based disparities and supporting educational continuity are essential for holistic pediatric cancer care.